Preclinical data show anti-CD24 macrophage checkpoint inhibitor promotes phagocytosis and shrinks tumors

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

Sheila Efron Taube honored by Brandeis with Alumni Achievement Award

Brandeis University has announced that Sheila Efron Taube ’63, a pioneer in cancer research, will receive the Alumni Achievement Award for outstanding contributions to their fields and society.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Clinical trial aims to address vaginal complaints after breast cancer diagnosis

The Alliance for Clinical Trials in Oncology is enrolling patients into a clinical trial aimed at helping women recover from the vaginal side effects of breast cancer treatment.

April 17, 2026

Vol.52 No.15

Clinical Roundup

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

FDA has approved Ponlimsi (denosumab-adet) as a biosimilar to Prolia.

April 03, 2026

Vol.52 No.13

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Preclinical data show anti-CD24 macrophage checkpoint inhibitor promotes phagocytosis and shrinks tumors

YOU MAY BE INTERESTED IN

FDA adds stereotactic breast biopsy needles to the shortage list

Sheila Efron Taube honored by Brandeis with Alumni Achievement Award

Clinical trial aims to address vaginal complaints after breast cancer diagnosis

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Renew today!

Subscriber content

Never miss an issue!

Login